← Leaderboards
David J Rawlings
Benaroya Research Inst At Virginia Mason
$37,323,092
Attributed
$41,267,733
Total exposure
24
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,153,101 · 25
By mechanism
P01$18,135,952 · 6
R01$17,213,477 · 6
DP3$4,411,432 · 1
PL1$4,340,874 · 1
T32$3,138,486 · 1
RL1$2,265,900 · 1
Top collaborators
- Keith B Elkon7 shared
- Hans-Peter Kiem5 shared
- Jane Hoyt Buckner4 shared
- Shaun William Jackson3 shared
- Tomas M Mustelin3 shared
- Fracisco A Bonilla1 shared
- Charlotte Cunningham-Rundles1 shared
- Raif Salim Geha1 shared
Most similar at Benaroya Research Inst At Virginia Mason
Same institution · by research overlap
- Peter S Linsley$7,467,441
- S Alice Long$5,134,395
- Karen M Cerosaletti$1,616,357
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseCellsHematopoietic Stem CellsGene TherapyB-LymphocytesIn VivoDesignSiteAnimal ModelVectorProgramsResearch PersonnelTransplantationViralReconstitutionMediatingGenesHematopoieticImmuneT-LymphocyteClinical TrialsImmunologic Deficiency SyndromesLaboratoriesGenerations
Grant awards (118)
Harnessing engineered T regulatory cells to promote beta cell health in T1D$975,699
R01 · FY2025 · DK
Research Training in Rheumatology$329,712
T32 · FY2025 · AR
Harnessing engineered T regulatory cells to promote beta cell health in T1D$975,699
R01 · FY2024 · DK
Research Training in Rheumatology$291,971
T32 · FY2024 · AR
Harnessing engineered T regulatory cells to promote beta cell health in T1D$975,699
R01 · FY2023 · DK
Research Training in Rheumatology$330,195
T32 · FY2023 · AR
Harnessing engineered T regulatory cells to promote beta cell health in T1D$993,436
R01 · FY2022 · DK
Lentiviral Gene Therapy and Genome Editing for Wiskott-Aldrich Syndrome$608,562
P01 · FY2022 · HL · contact PI
Research Training in Rheumatology$410,073
T32 · FY2022 · AR
Lentiviral Gene Therapy and Genome Editing for Wiskott-Aldrich Syndrome$611,466
P01 · FY2021 · HL · contact PI
Research Training in Rheumatology$360,172
T32 · FY2021 · AR
Lentiviral Gene Therapy and Genome Editing for Wiskott-Aldrich Syndrome$614,320
P01 · FY2020 · HL · contact PI
Lentiviral Gene Therapy and Genome Editing for Wiskott-Aldrich Syndrome$621,596
P01 · FY2019 · HL · contact PI
Research Training in Rheumatology$277,888
T32 · FY2019 · AR
Core A: Immune Function Studies$147,351
P01 · FY2019 · HL · contact PI
Lentiviral Gene Therapy and Genome Editing for Wiskott-Aldrich Syndrome$644,283
P01 · FY2018 · HL · contact PI
Research Training in Rheumatology$274,876
T32 · FY2018 · AR
Mechanisms underlying TACI-dependent activation of immature transitional B cells in BAFF-driven humoral autoimmunity$235,375
R21 · FY2018 · AI · contact PI
Core A: Immune Function Studies$148,581
P01 · FY2018 · HL · contact PI
Mechanisms underlying TACI-dependent activation of immature transitional B cells in BAFF-driven humoral autoimmunity$282,450
R21 · FY2017 · AI · contact PI
Research Training in Rheumatology$279,317
T32 · FY2017 · AR
Core A: Immune Function Studies$149,948
P01 · FY2017 · HL · contact PI
Analysis of B-Cell Tolerance in Wiskott-Aldrich Syndrome Following Stem Cell Transplantation$76,928
U54 · FY2017 · AI · contact PI
An integrated strategy to define the functional and synergistic impact of T1D causal variants$4,411,432
DP3 · FY2016 · DK · contact PI
Foamy Viral Gene Therapy for X-linked Severe Combined Immune Deficiency$2,468,421
P01 · FY2016 · AI · contact PI
Research Training in Rheumatology$308,360
T32 · FY2016 · AR
Pre-clinical Modeling of Foamy Viral gene Therapy for Murine and Human SCID-X1$231,489
P01 · FY2016 · AI · contact PI
Core A: Immune Function Studies$151,175
P01 · FY2016 · HL · contact PI
Analysis of B-Cell Tolerance in Wiskott-Aldrich Syndrome Following Stem Cell Transplantation$97,500
U54 · FY2016 · AI · contact PI
Administrative Core$58,442
P01 · FY2016 · AI · contact PI
Foamy Viral Gene Therapy for X-linked Severe Combined Immune Deficiency$2,468,981
P01 · FY2015 · AI · contact PI
Lentiviral Gene Therapy of X-Linked Agammaglobulinemia$676,468
R01 · FY2015 · AI · contact PI
Research Training in Rheumatology$275,922
T32 · FY2015 · AR
Pre-clinical Modeling of Foamy Viral gene Therapy for Murine and Human SCID-X1$231,016
P01 · FY2015 · AI · contact PI
Core A: Immune Function Studies$171,523
P01 · FY2015 · HL · contact PI
Analysis of B-Cell Tolerance in Wiskott-Aldrich Syndrome Following Stem Cell Transplantation$97,500
U54 · FY2015 · AI · contact PI
Administrative Core$58,155
P01 · FY2015 · AI · contact PI
Foamy Viral Gene Therapy for X-linked Severe Combined Immune Deficiency$2,472,869
P01 · FY2014 · AI · contact PI
Lentiviral Gene Therapy of X-Linked Agammaglobulinemia$588,718
R01 · FY2014 · AI · contact PI
Pre-clinical Modeling of Foamy Viral gene Therapy for Murine and Human SCID-X1$391,790
P01 · FY2014 · AI · contact PI
GLILD in CVID$279,802
R34 · FY2014 · AI
Analysis of B-Cell Tolerance in Wiskott-Aldrich Syndrome Following Stem Cell Transplantation$137,129
U54 · FY2014 · AI · contact PI
Administrative Core$98,627
P01 · FY2014 · AI · contact PI
Lentiviral Gene Therapy of X-Linked Agammaglobulinemia$87,750
R01 · FY2014 · AI · contact PI
Foamy Viral Gene Therapy for X-linked Severe Combined Immune Deficiency$2,089,212
P01 · FY2013 · AI · contact PI
Lentiviral Gene Therapy of X-Linked Agammaglobulinemia$553,395
R01 · FY2013 · AI · contact PI
Pre-clinical Modeling of Foamy Viral gene Therapy for Murine and Human SCID-X1$217,818
P01 · FY2013 · AI · contact PI
Administrative Core$54,833
P01 · FY2013 · AI · contact PI
Foamy Viral Gene Therapy for X-linked Severe Combined Immune Deficiency$2,385,885
P01 · FY2012 · AI · contact PI
Lentiviral Gene Therapy for Wiskott-Aldrich Syndrome$715,496
R01 · FY2012 · AI · contact PI
Lentiviral Gene Therapy of X-Linked Agammaglobulinemia$588,718
R01 · FY2012 · AI · contact PI
Pre-clinical Modeling of Foamy Viral gene Therapy for Murine and Human SCID-X1$250,148
P01 · FY2012 · AI · contact PI
Administrative Core$62,971
P01 · FY2012 · AI · contact PI
Cell and Virus CORE$845,477
PL1 · FY2011 · HL · contact PI
Lentiviral Gene Therapy for Wiskott-Aldrich Syndrome$715,509
R01 · FY2011 · AI · contact PI
Gene Repair in Murine Hematopoietic Stem Cells (Component 6 of 11)$450,450
RL1 · FY2011 · HL · contact PI
Interdisciplinary Training in Genome Engineering(Component 10 of 11) RL9$132,116
RL9 · FY2011 · HL · contact PI
Interdisciplinary Training in Genome Engineering (Component 10 of 11)TL1$82,876
TL1 · FY2011 · HL · contact PI
Cell and Virus CORE$822,089
PL1 · FY2010 · HL · contact PI
Lentiviral Gene Therapy for Wiskott-Aldrich Syndrome$803,587
R01 · FY2010 · AI · contact PI
Gene Repair in Murine Hematopoietic Stem Cells (Component 6 of 11)$450,450
RL1 · FY2010 · HL · contact PI
B cell function and phenotype as predictors of therapeutic response to rituximab$393,556
RC4 · FY2010 · DK · contact PI
Core--Immune Function Studies$177,991
P01 · FY2010 · HL · contact PI
Interdisciplinary Training in Genome Engineering(Component 10 of 11) RL9$128,156
RL9 · FY2010 · HL · contact PI
Interdisciplinary Training in Genome Engineering (Component 10 of 11)TL1$102,812
TL1 · FY2010 · HL · contact PI
Cell and Virus CORE$75,000
PL1 · FY2010 · HL · contact PI
Lentiviral Gene Therapy for Wiskott-Aldrich Syndrome$993,911
R01 · FY2009 · AI · contact PI
Cell and Virus CORE$799,169
PL1 · FY2009 · HL · contact PI
Gene Repair in Murine Hematopoietic Stem Cells (Component 6 of 11)$455,000
RL1 · FY2009 · HL · contact PI
Lentiviral Gene Therapy of X-linked Agammaglobulinemia$398,458
R56 · FY2009 · AI · contact PI
Core--Immune Function Studies$172,701
P01 · FY2009 · HL · contact PI
Interdisciplinary Training in Genome Engineering(Component 10 of 11) RL9$165,578
RL9 · FY2009 · HL · contact PI
Cell and Virus CORE$75,420
PL1 · FY2009 · HL · contact PI
Interdisciplinary Training in Genome Engineering (Component 10 of 11)TL1$51,652
TL1 · FY2009 · HL · contact PI
Cell and Virus CORE$721,379
PL1 · FY2008 · HL · contact PI
Gene Repair in Murine Hematopoietic Stem Cells (Component 6 of 11)$455,000
RL1 · FY2008 · HL · contact PI
Lentiviral Gene Therapy of X-linked Agammaglobulinemia$367,420
R01 · FY2008 · HL · contact PI
Regulation of B Cell Development and Signaling by Btk$324,065
R01 · FY2008 · HD · contact PI
Model for Gene Therapy in X-linked Agammaglobulinemia$297,611
R01 · FY2008 · CA · contact PI
Lentiviral Gene Therapy for Wiskott-Aldrich Syndrome$286,015
R01 · FY2008 · AI · contact PI
Cell and Virus CORE$175,000
PL1 · FY2008 · HL · contact PI
Core--Immune Function Studies$164,332
P01 · FY2008 · HL · contact PI
Interdisciplinary Training in Genome Engineering(Component 10 of 11) RL9$115,630
RL9 · FY2008 · HL · contact PI
Interdisciplinary Training in Genome Engineering (Component 10 of 11)TL1$49,514
TL1 · FY2008 · HL · contact PI
Cell and Virus CORE$827,340
PL1 · FY2007 · HL · contact PI
Lentiviral Gene Therapy for Wiskott-Aldrich Syndrome$614,879
R56 · FY2007 · AI · contact PI
Gene Repair in Murine Hematopoietic Stem Cells$455,000
RL1 · FY2007 · HL · contact PI
Lentiviral Gene Therapy of X-linked Agammaglobulinemia$367,420
R01 · FY2007 · HL · contact PI
Regulation of B Cell Development and Signaling by Btk$330,679
R01 · FY2007 · HD · contact PI
Model for Gene Therapy in X-linked Agammaglobulinemia$297,611
R01 · FY2007 · CA · contact PI
Core--Immune Function Studies$96,614
P01 · FY2007 · HL · contact PI
Interdisciplinary Training in Genome Engineering$49,514
TL1 · FY2007 · HL · contact PI
PKD2 involvement in the Btk-PKCBeta-NFkappaBeta pathway*$47,030
R03 · FY2007 · TW · contact PI
Interdisciplinary Training in Genome Engineering$10,491
RL9 · FY2007 · HL · contact PI
Lentiviral Gene Therapy of X-linked Agammaglobulinemia$378,394
R01 · FY2006 · HL · contact PI
Regulation of B Cell Development and Signaling by Btk$340,555
R01 · FY2006 · HD · contact PI
Model for Gene Therapy in X-linked Agammaglobulinemia$306,499
R01 · FY2006 · CA · contact PI
Core--Immune Function Studies$114,852
P01 · FY2006 · HL · contact PI
PKD2 involvement in the Btk-PKCBeta-NFkappaBeta pathway*$48,434
R03 · FY2006 · TW · contact PI
Lentiviral Gene Therapy of X-linked Agammaglobulinemia$387,500
R01 · FY2005 · HL
Regulation of B Cell Development and Signaling by Btk$348,750
R01 · FY2005 · HD
Model for Gene Therapy in X-linked Agammaglobulinemia$313,875
R01 · FY2005 · CA
PKD2 involvement in the Btk-PKCBeta-NFkappaBeta pathway*$49,600
R03 · FY2005 · TW
Lentiviral Gene Therapy of X-linked Agammaglobulinemia$387,500
R01 · FY2004 · HL
Regulation of B Cell Development and Signaling by Btk$348,750
R01 · FY2004 · HD
Model for Gene Therapy in X-linked Agammaglobulinemia$313,875
R01 · FY2004 · CA
REGULATION OF B CELL DEVELOPMENT AND SIGNALING BY BTK$265,683
R01 · FY2003 · HD
MODEL FOR GENE THERAPY IN X LINKED AGAMMAGLOBULINEMIA$251,799
R01 · FY2003 · CA
MODEL FOR GENE THERAPY IN X LINKED AGAMMAGLOBULINEMIA$74,420
R01 · FY2003 · CA
REGULATION OF B CELL DEVELOPMENT AND SIGNALING BY BTK$258,154
R01 · FY2002 · HD
MODEL FOR GENE THERAPY IN X LINKED AGAMMAGLOBULINEMIA$245,287
R01 · FY2002 · CA
MODEL FOR GENE THERAPY IN X LINKED AGAMMAGLOBULINEMIA$72,312
R01 · FY2002 · CA
MODEL FOR GENE THERAPY IN X LINKED AGAMMAGLOBULINEMIA$243,187
R01 · FY2001 · CA
REGULATION OF B CELL DEVELOPMENT AND SIGNALING BY BTK$197,139
R01 · FY2001 · HD
REGULATION OF B CELL DEVELOPMENT AND SIGNALING BY BTK$62,874
R01 · FY2001 · HD
MODEL FOR GENE THERAPY IN X LINKED AGAMMAGLOBULINEMIA$33,293
R01 · FY2001 · CA
REGULATION OF B CELL DEVELOPMENT AND SIGNALING BY BTK$257,169
R01 · FY2000 · HD
MODEL FOR GENE THERAPY IN X LINKED AGAMMAGLOBULINEMIA$211,556
R01 · FY2000 · CA